Lung Cancer Trials Ask AI to find trials
CompletedNot applicableNCT05018208
Official study title

Remote Monitoring in Cancer Care: A Platform Study

Study summary

This study investigates a device that closely monitors vital signs, as well as a smartphone application (app) that allows patients to respond to different questions and tests that will monitor for new symptoms. This study may help researchers understand if wearing the device is a better tool than standard vital sign assessment tools done only while at the doctor's office or hospital, and if using the smartphone app is a better tool than standard assessment tools used while in the doctor's office or hospital.

Ask AI to explain this study
Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedComputer-Assisted Intervention and Patient Monitoring

Plus 1 other study approaches.

Who it may be forHead and Neck Carcinoma · Hematopoietic and Lymphoid Cell Neoplasm

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Oct 30, 2025 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Observational

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Mayo Clinic

Study sponsor

01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
Mayo Clinic
Interventions being studied
Other: Computer-Assisted Intervention; Procedure: Patient Monitoring; Other: Questionnaire Administration
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • ARM 1: Age \>= 18 years
  • ARM 1: Provide written informed consent
  • ARM 1: Patients undergoing commercial CAR-T cell therapy in an outpatient setting
  • ARM 2: Age \>= 18 years
  • ARM 2: Provide written informed consent
  • ARM 2: Patients with a plan to undergo radiation therapy for lung, gastrointestinal, or head and neck cancer
Reasons someone may not be able to joinExclusion criteria
  • ARM 1: Non-English speaking
  • ARM 1: Planned initiation of lymphodepleting chemotherapy in the inpatient setting
  • ARM 2: Non-English speaking

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Mayo Clinic in RochesterRochester, Minnesota

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 30, 2025. Always confirm current availability with the study team.

View original record ↗